95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Pharmacol.
Sec. Ethnopharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1576286
This article is part of the Research Topic Herbal Medicines and Their Metabolites as Therapeutic Agents in Osteolytic Disease Management View all 8 articles
Research Advances in Omics-Based Traditional Chinese Medicine for the Prevention and Treatment of Metabolic Bone Diseases
Provisionally accepted- 1 Changchun University of Chinese Medicine, Changchun, China
- 2 The Third Affiliated Clinical Hospital of Changchun University of Traditional Chinese Medicine, Jilin, China
- 3 Changchun Hospital of Chinese Medicine, Changchun, China
- 4 The Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin Province, China
Metabolic bone disease (MBD), as one of the most severe metabolic disorders, remains a focal point and challenge in medical research. Numerous studies have demonstrated the efficacy of Traditional Chinese Medicine (TCM) in preventing and treating MBD. However, the inherent complexity of TCM metabolites poses significant limitations in elucidating their mechanisms of action. The advancement of omics technologies, including metabolomics, proteomics, and transcriptomics, has greatly facilitated research on MBD. These approaches enable the identification of potential biomarkers and the exploration of metabolic pathways and mechanisms underlying TCM interventions for MBD. Evidence indicates that TCM monomers, single botanical drugs, and herbal formulations are effective, safe, and well-tolerated in MBD prevention and treatment. This review summarizes recent applications and key findings of transcriptomics, proteomics, and metabolomics in studying the mechanisms of TCM interventions for MBD. It highlights the role of omics technologies in uncovering relevant metabolites and pathways under TCM treatment, providing valuable insights and clinical references for TCM-based strategies in managing MBD.
Keywords: metabolic bone disease, Traditional Chinese Medicine ( TCM ), Metabolomics, Proteomics, Transcriptomics
Received: 13 Feb 2025; Accepted: 25 Mar 2025.
Copyright: © 2025 Cai, Jiang, Zhao and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Changwei Zhao, Changchun University of Chinese Medicine, Changchun, China
Xiaoling Zhou, The Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, 130021, Jilin Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.